Mylan $264 Million EpiPen Price-Gouge Deal Gets Final Court Nod

Consumers and insurers leading price-gouging litigation over the EpiPen, a treatment for life-threatening allergic reactions, won final approval from a federal judge in Kansas for their $264 million settlement with affiliates of Mylan NV, which markets the device.

Judge Daniel D. Crabtree signed off on the deal Monday, resolving class action antitrust claims brought against Mylan in the US District Court for the District of Kansas of behalf of “end payers” like insurers, pension funds, and consumers.

The agreement broadly resembles a previous $345 million pact with Pfizer Inc. affiliates that formerly manufactured the EpiPen. Crabtree approved the Pfizer ...